USO RACIONAL DE MEDICAMENTOS, CARAJO
En Europa, hoy se acaba de celebrar el “Día Europeo para el uso prudente de los antibioticos”, iniciativa por demás plausible en estos tiempos en que solemos usar ciprofloxacina hasta en inofensivas diarreas. El gran problema creo, es que solemos ubicar la anamnesis y el examen clínico en un espacio cada vez más restringido. Sabemos casi todo de las ultimas terapéuticas pero nuestro ejercicio diagnostico cada vez está mas devaluado. Una buena terapéutica nunca es buena si reposa sobre un mal diagnostico.
La European Centre for Disease Prevention and Control (ECDC) y la European Medicines Agency (EMEA) elaboraron el informe técnico “The bacterial challenge: time to react” que se basa en algunas consideraciones:……..
There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics to tackle the problem.
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious infections in humans and reaches 25% or more in several EU Member States.
• Resistance is increasing in the EU among certain Gram-negative bacteria such as recently observed for Escherichia coli.
• Each year, about 25 000 patients die in the EU from an infection with the selected multidrug-resistant bacteria.
........The following antibiotic-resistant bacteria were selected because they frequently are responsible for bloodstream infections and because the associated antibiotic resistance trait is, in most cases, a marker for multiple resistance to antibiotics:
• Staphylococcus aureus, methicillin resistance (MRSA);
• S. aureus, vancomycin intermediate resistance and vancomycin resistance (VISA/VRSA);
• Enterococcus spp. (e.g. Enterococcus faecium), vancomycin resistance (VRE);
• Streptococcus pneumoniae, penicillin resistance (PRSP);
• Enterobacteriaceae (e.g. Escherichia coli, Klebsiella pneumoniae), third-generation cephalosporin resistance;
• Enterobacteriaceae (e.g. K. pneumoniae), carbapenem resistance; and
• Non-fermentative Gram-negative bacteria (e.g. Pseudomonas aeruginosa), carbapenem resistance.
¡¡¡¡¡¡¡Escalofriante!!!!!!!!, ¿ no les parece?
Sus conclusiones son aun mas……..
• There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics to tackle the problem.
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious infections in humans.
• Resistance is increasing among certain Gram-negative bacteria.
• Infections caused by multidrug-resistant bacteria are associated with excess morbidity and mortality.
• Infections caused by multidrug-resistant bacteria are associated with substantial extra costs.
• Very few antibacterial agents with new mechanisms of action are under development to meet the challenge of multidrug resistance.
• There is a particular lack of new agents to treat infections due to multidrug-resistant Gram-negative bacteria.
• A European and global strategy to address this gap is urgently needed.
Entonces, a ser fanáticos del uso racional de antibioticos.
La European Centre for Disease Prevention and Control (ECDC) y la European Medicines Agency (EMEA) elaboraron el informe técnico “The bacterial challenge: time to react” que se basa en algunas consideraciones:……..
There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics to tackle the problem.
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious infections in humans and reaches 25% or more in several EU Member States.
• Resistance is increasing in the EU among certain Gram-negative bacteria such as recently observed for Escherichia coli.
• Each year, about 25 000 patients die in the EU from an infection with the selected multidrug-resistant bacteria.
........The following antibiotic-resistant bacteria were selected because they frequently are responsible for bloodstream infections and because the associated antibiotic resistance trait is, in most cases, a marker for multiple resistance to antibiotics:
• Staphylococcus aureus, methicillin resistance (MRSA);
• S. aureus, vancomycin intermediate resistance and vancomycin resistance (VISA/VRSA);
• Enterococcus spp. (e.g. Enterococcus faecium), vancomycin resistance (VRE);
• Streptococcus pneumoniae, penicillin resistance (PRSP);
• Enterobacteriaceae (e.g. Escherichia coli, Klebsiella pneumoniae), third-generation cephalosporin resistance;
• Enterobacteriaceae (e.g. K. pneumoniae), carbapenem resistance; and
• Non-fermentative Gram-negative bacteria (e.g. Pseudomonas aeruginosa), carbapenem resistance.
¡¡¡¡¡¡¡Escalofriante!!!!!!!!, ¿ no les parece?
Sus conclusiones son aun mas……..
• There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics to tackle the problem.
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious infections in humans.
• Resistance is increasing among certain Gram-negative bacteria.
• Infections caused by multidrug-resistant bacteria are associated with excess morbidity and mortality.
• Infections caused by multidrug-resistant bacteria are associated with substantial extra costs.
• Very few antibacterial agents with new mechanisms of action are under development to meet the challenge of multidrug resistance.
• There is a particular lack of new agents to treat infections due to multidrug-resistant Gram-negative bacteria.
• A European and global strategy to address this gap is urgently needed.
Entonces, a ser fanáticos del uso racional de antibioticos.
Comentarios